​On 1st Dec 2016, Beijing Genetech, subsidiary of Uni-Bio Science Group entered into a strategic agreement to co-develop promising oral anti-diabetic drugs (OAD).

On 27th Jun 2016, sales Partnership with CR Zizhu can potentially access 5 times the number of hospitals in a short period of time.

On 24th Nov 2015, Uni-Bio Science acquired exclusive global rights to manufacture and commercialise.